Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.

The user is experiencing sleep issues after starting finasteride for hair loss and is considering using magnesium or melatonin to improve sleep. Other users suggest that sleep disturbances are a common side effect initially, but may improve over time.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The user experienced significant hair regrowth using 1mg oral finasteride daily and recently added minoxidil 5% to address remaining gaps. They reported no significant side effects, attributing any perceived changes to weight fluctuations rather than the medication.

A user shared their 4-month progress using 2.5mg minoxidil, 1mg finasteride, and 10mg biotin, noting slight testicular discomfort initially but no significant hairline changes yet. Another user reported similar treatment results, with hair darkening at the scalp center and small temple hairs.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

User DeadRay9 reports good progress on finasteride and ketoconazole, with irregular microneedling. They take 1.25mg finasteride, experienced increased libido, and saw improvements at 3-5 months.

Vitamin D supplementation may have led to slight hair regrowth and density improvement. Other treatments discussed include finasteride, minoxidil, and maintaining optimal vitamin D levels.

The conversation is about a user's progress with hair loss treatment using 0.5mg oral finasteride and 50ml of Essegen-F topical finasteride daily, with improved hair density and minimal side effects. The user also used ketoconazole shampoo for seborrheic dermatitis and noticed significant hair regrowth over 1.5 years.

The user plans to take oral minoxidil 5mg, topical minoxidil, finasteride, dutasteride 0.5mg, and various vitamins for hair loss. A caution was given about the high daily dosage of vitamin D3.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.

A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.

User applied Xyon fin topical gel daily, used Augstinus Bader shampoo, conditioner, and scalp treatment, and applied argan oil twice a week. No Minoxidil, no dermarolling, and no side effects were reported.

A user started finasteride and zinc for hair loss, planning to add ketoconazole. They hope this combination will be effective.

A 22-year-old male shared his positive experience using 1 mg finasteride daily for two years, noting significant hair thickening and texture improvement without side effects. Other users discussed their own hair loss treatments, including finasteride and minoxidil, and shared encouragement and advice.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

User shares 9-month progress using topical Fin/Min formula (10% Min, 0.1% Fin) for hair loss, with significant improvement in crown area. Others discuss experiences, side effects, and application methods for the treatment.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

A 26-year-old male has been using finasteride for 4.5 years to maintain hair and recently started taking dutasteride weekly due to increased hair shedding. He plans to gradually switch to dutasteride while monitoring side effects and hair changes.